bryostatin 1 + gemcitabine

Bryostatin 1 + gemcitabine is an investigational combination therapy consisting of two agents with distinct mechanisms of action. Bryostatin 1 is a macrocyclic lactone derived from marine invertebrates that acts as a modulator and inhibitor of protein kinase C (PKC), exhibiting both direct antitumor and immunomodulatory effects. It can induce differentiation, inhibit proliferation, and promote apoptosis in various cancer cell types. Gemcitabine is a nucleoside analog (antimetabolite) that interferes with DNA synthesis, leading to inhibition of tumor cell replication and induction of apoptosis. Preclinical studies have shown that bryostatin 1 can enhance the cytotoxic effects of gemcitabine by modulating PKC signaling pathways, resulting in increased antiproliferative and pro-apoptotic activity in cancer cells[2][4]. Clinical trials have demonstrated that this combination is generally well tolerated with manageable toxicity profiles; partial responses and disease stabilization have been observed in heavily pretreated patients with advanced solid tumors[1][5].